Las Vegas, Nev. — MountainView Hospital achieved a major milestone in cancer care completing its 100th stem cell transplant, including both allogeneic and autologous stem cell transplants through the Sarah Cannon Transplant and Cellular Therapy Program at MountainView Hospital — the first of its kind in the state.
In 2025, MountainView Hospital became the first hospital in Nevada to offer advanced blood cancer treatments such as allogeneic stem cell transplants and CAR T-cell therapy through its Sarah Cannon Transplant & Cellular Therapy Program. Prior to the program’s launch, patients in Nevada often had to leave the state — sometimes for months at a time — to access these life-saving therapies.
“Reaching our 100th transplant is a significant milestone and powerful reminder of why this program was created,” said MountainView Hospital Chief Executive Officer Alexis Mussi. “Patients no longer have to travel out of state for highly complex, life-saving blood cancer care. They can now receive world-class treatment right here at home, surrounded by their families and support systems.”
In 2024, more than 1,200 patients left the state for inpatient cancer care. In the last year prior to opening the Sarah Cannon Transplant and Cellular Therapy Program at MountainView Hospital, 132 patients with various types of blood cancers had to travel out of state for care.
“Stem cell transplants — both autologous and allogeneic — are among the most effective therapies we have for treating and, in many cases, curing blood cancers,” said Dr. Carolyn Mulroney, medical director of the Sarah Cannon Transplant & Cellular Therapy Program. “Having these treatments available in Nevada removes a significant barrier to care for patients who previously had no choice but to leave the state.”
The program offers a full continuum of care for patients with blood cancers, including autologous stem cell transplants, allogeneic stem cell transplants and CAR T-cell therapy, a cutting-edge immunotherapy that uses a patient’s own genetically modified immune cells to target cancer.
It is supported by MountainView’s first-of-its-kind 12,000-square-foot day hospital, designed specifically for blood cancer patients to receive transfusions, procedures and outpatient therapies in a specialized, patient-centered environment.
The program also features a dedicated oncology nurse navigation program to guide patients through their entire cancer journey. Specially trained nurses serve as an anchor for support and information, attend patient appointments, and participate in multi-disciplinary meetings to remove barriers to care.
The Sarah Cannon Cancer Network gives patients access to the best minds across the country. “Our network sees 130,000 newly diagnosed cancer patients annually, and our specialty provider leadership teams meet frequently to review and revise cancer treatment pathways and incorporate the latest research data to provide the best outcomes,” said Tom Cronin, regional vice president of oncology services for the Sarah Cannon Cancer Network here locally.
Patients and physicians who want to learn more about MountainView’s program can call (702) 962-2106 or find out more at Transplant and cellular therapy website.